Anti-shedding hair growth wet wipes and methods of making the same

Abstract

The present application belongs to the technical field of hair care pharmaceutical preparations, external hair loss prevention and care products, and external pharmaceutical preparations, and discloses a hair loss prevention and growth wet wipe and a preparation method thereof. The wet wipe is composed of a pure cotton non-woven carrier and a compound medicinal solution for infiltrating the carrier. The compound medicinal solution takes minoxidil and finasteride as core active components, and is combined with a dissolution aid, a transdermal enhancer, a moisturizing stabilizer, a bacteriostatic preservative, and purified water. The components are scientifically compounded and synergize with each other, and the wet wipe has the advantages of efficacy, permeability, stability, and mildness.

Description

Technical Field

[0001] This invention relates to the technical fields of hair care pharmaceutical preparations, topical anti-hair loss shampoo and conditioner products, and topical pharmaceutical preparations, and more specifically to an anti-hair loss and hair growth wipe containing minoxidil and finasteride and its preparation method. Background Technology

[0002] Hair loss is a common skin problem in modern times. Among them, androgenetic alopecia and seborrheic alopecia account for more than 90% of the hair loss population. They are mainly caused by excessive dihydrotestosterone in the scalp, hair follicle atrophy and degeneration, and shortened hair growth phase. They are characterized by high incidence, young age of onset, and easy recurrence.

[0003] Currently, the mainstream topical medications for preventing hair loss in clinical practice are minoxidil and finasteride: minoxidil can dilate scalp capillaries, improve blood supply to hair follicles, prolong the hair growth phase, and stimulate the revival of dormant hair follicles to achieve hair growth; finasteride can specifically inhibit 5α-reductase, reduce the production of dihydrotestosterone in the scalp, and block hair follicle atrophy from the root to achieve hair loss prevention and hair strengthening. The two have complementary pharmacological effects and synergistic effects, and are recognized as the golden combination for preventing hair loss.

[0004] Most commercially available products are minoxidil tincture and finasteride topical solution, which have several inherent drawbacks: 1. The dosage form is inconvenient to use, requiring manual application and massage. The liquid is highly fluid and easily flows onto the forehead and face, staining the skin and clothing, resulting in waste. 2. It is difficult to accurately control the dosage when applying manually. Too much liquid can easily cause scalp itching and redness, while insufficient dosage will not achieve the desired therapeutic effect. 3. The liquid is prone to oxidation and volatilization after opening, and the active ingredients have poor stability. The efficacy decreases significantly with long-term storage. 4. They are inconvenient to carry and are only suitable for home use, failing to meet the daily maintenance needs of outings, business trips, and office settings.

[0005] Meanwhile, existing single-ingredient hair loss prevention products have limited efficacy, only achieving single effects such as preventing hair loss or promoting hair growth. Treatment cycles are long and results are slow. Compound preparations are mostly traditional liquid formulations, failing to address the pain points of poor user experience and limited applicability. While wet wipes are widely used in topical care due to their convenience, hygiene, and controllable dosage, there are currently no dedicated medicated wet wipes that simultaneously combine minoxidil and finasteride for hair loss treatment, creating a technological gap in the market.

[0006] Therefore, given the shortcomings of existing technologies, developing a hair loss prevention and hair growth medicated wipe that features synergistic dual active ingredients, convenient use, precise dosage, strong stability, and applicability across all scenarios has significant market value and clinical application significance. Summary of the Invention

[0007] In view of this, the purpose of this invention is to overcome the shortcomings of existing anti-hair loss liquids, such as cumbersome use, uneven dosage, easy contamination, single efficacy, limited application scenarios, and poor stability. This invention provides an anti-hair loss and hair growth wipe and its preparation method, achieving the dual effects of preventing hair loss at its source and promoting efficient hair growth. It also significantly improves the product's ease of use, safety, and practicality, overcoming the shortcomings of existing liquid topical preparations, such as easy dripping, uncontrollable dosage, inconvenience in carrying, and limited efficacy of single ingredients. Furthermore, this invention provides a compound anti-hair loss and hair growth wipe that achieves synergistic effects of two active ingredients, with a user-friendly dosage form and excellent stability.

[0008] One objective of this invention is to provide a hair loss prevention and hair growth wipe, comprising a non-woven fabric carrier and a compound medicinal solution impregnated on the carrier; the compound medicinal solution is composed of the following components by mass percentage:

[0009] Minoxidil 1.0%–5.0% Finasteride 0.01%–0.8% Cosolvent 15%–35% Transdermal penetration enhancer 1.0%–3.0% Moisturizing stabilizer 5.0%~15.0% Antibacterial and preservative agent: 0.1%–0.5% Add purified water to bring the volume to 100%.

[0010] Preferably, the compound drug solution is composed of the following components by mass percentage: minoxidil 3.0%, finasteride 0.25%, solubilizer 25%, transdermal penetration enhancer 2.0%, moisturizing stabilizer 10%, antibacterial preservative 0.3%, and the balance being purified water.

[0011] Preferably, the co-solvent is selected from one or more of propylene glycol, 1,3-butanediol, and anhydrous ethanol.

[0012] Preferably, the transdermal penetration enhancer is selected from one or more of azone, menthol, and polyethylene glycol 400.

[0013] Preferably, the moisturizing stabilizer is selected from one or more of glycerin, panthenol, and sodium hyaluronate.

[0014] Preferably, the antibacterial preservative is phenoxyethanol, ethylhexylglycerin, or a mixture of phenoxyethanol and ethylhexylglycerin.

[0015] Preferably, the mass ratio of phenoxyethanol to ethylhexylglycerin in the compound system is 2:1 to 4:1. Within this mass ratio range, the synergistic antibacterial effect is optimal, reducing the risk of skin irritation from using phenoxyethanol alone. If the proportion of phenoxyethanol is too low, the overall preservative efficacy is insufficient; if the proportion of ethylhexylglycerin is too high, it will increase the stickiness of the formula and affect the skin feel of the wipes. A further preferred ratio is 3:1.

[0016] Preferably, the nonwoven fabric is a spunlace nonwoven fabric with a basis weight of 50-80 g / m². 2 The material is pure cotton or viscose fiber, which is not easy to shed lint. The amount of medicine soaked in a single non-woven fabric is controlled to be 2.0-3.0g.

[0017] The second objective of this invention is to provide a method for preparing anti-hair loss and hair growth wipes, comprising the following steps: S1. Raw material pretreatment; S2. Preparation of compound drug solution: Under a light-protected and sterile environment, add solubilizer and moisturizing stabilizer to preheated purified water and stir to dissolve; then add minoxidil and finasteride and stir thoroughly until completely dissolved; add transdermal penetration enhancer and antibacterial preservative in sequence, mix evenly and let stand to defoam; S3. Non-woven fabric impregnation: Non-woven fabric is impregnated with negative pressure to absorb the drug solution; S4. Individually sealed and light-proof packaging yields the finished anti-hair loss and hair growth wipes.

[0018] Preferably, the temperature of the preheated purified water is 35-45°C, the stirring speed is 300-500 r / min, and the ambient temperature for impregnating the nonwoven fabric is 25-30°C.

[0019] The anti-hair loss and hair growth wipes of the present invention are used in the preparation of topical medications for the prevention or treatment of androgenetic alopecia and seborrheic alopecia.

[0020] The hair loss prevention and hair growth wipes containing minoxidil and finasteride provided by this invention are composed of a compound medicinal solution made of pure cotton non-woven fabric carrier and an impregnation carrier. The compound medicinal solution takes minoxidil and finasteride as the core active ingredients, combined with solubilizers, transdermal penetration enhancers, moisturizing stabilizers, antibacterial preservatives and purified water. The components are scientifically compounded and work synergistically to balance efficacy, permeability, stability and gentleness.

[0021] Among them, minoxidil is limited to 1.0% to 5.0%, which can maximize the stimulation of hair follicle growth while avoiding scalp irritation caused by high concentrations; finasteride is limited to 0.01% to 0.8%, which is a safe dose for topical use. It can effectively inhibit scalp 5α-reductase, has no systemic side effects, and is suitable for long-term topical use.

[0022] The solubilizer is a combination of polyol and ethanol, which can significantly improve the water solubility of minoxidil and finasteride, prevent the active ingredients from precipitating, and ensure the uniformity and stability of the drug solution. The transdermal penetration enhancer can break through the scalp stratum corneum barrier and improve the transdermal absorption rate of active ingredients. Compared with ordinary drug solutions, the drug utilization rate is increased by more than 30%.

[0023] Moisturizing stabilizers can balance the scalp's oil and water levels, soothe mild irritation from medications, improve dry scalp and excessive oil production associated with seborrheic alopecia, and enhance the storage stability of the medication solution, extending the product's shelf life.

[0024] This invention also provides its proprietary preparation method, which uses low-temperature light-protected preparation, negative pressure uniform impregnation, and independent sealing and packaging processes to maximize the preservation of the efficacy of active ingredients and ensure that each wipe has a uniform amount of medicine and stable quality.

[0025] As can be seen from the above technical solution, compared with the prior art, the present invention has the following significant innovations and beneficial effects: 1. Dual-effect synergy for stronger efficacy. This invention is the first to combine minoxidil with the hair growth mechanism and finasteride's hair loss prevention mechanism. The two components are precisely formulated to work from three dimensions: inhibiting the root cause of hair loss, activating dormant hair follicles, and prolonging the hair growth phase. This solves the problem of slow and limited effects of single components and has significant improvement effects on androgenetic alopecia, seborrheic alopecia, and mild postpartum hair loss.

[0026] 2. Innovative dosage form for ultimate convenience of use. Abandoning traditional tinctures and solutions, this product uses a wet wipe format, with each wipe individually packaged. It is ready to use immediately, requiring no mixing or rinsing, and can be used anytime, anywhere, whether you are out, at the office, or on a business trip. The non-woven fabric adheres to the scalp for wiping and massaging, ensuring the medicine is evenly applied without dripping or staining clothes, thus completely solving the problems of pollution and waste associated with traditional medicines.

[0027] 3. Precise dosage, safe and controllable. By using a standardized immersion process, the amount of medicine carried in each wipe is fixed, which solves the problem of uneven dosage caused by manual application, avoids the risk of scalp allergies and irritation caused by excessive dosage, and ineffective care caused by insufficient dosage. It is safe and stable for long-term use and is suitable for daily maintenance and hair loss treatment.

[0028] 4. Excellent permeability and high utilization rate It incorporates a proprietary transdermal penetration system that can quickly penetrate the scalp's stratum corneum, promoting the targeted action of active ingredients on the hair follicle roots, reducing drug residue on the surface, and significantly improving drug utilization. Compared to traditional application methods, it offers superior anti-hair loss and hair regrowth effects at the same dosage.

[0029] 5. High stability and long shelf life The formula uses moisturizing stabilizers and cosolvents in synergy to effectively prevent the oxidation, precipitation, and degradation of minoxidil and finasteride. Combined with independent light-proof and sealed packaging, the active ingredients are stable under normal temperature storage conditions, and the shelf life can reach 24 months, far exceeding that of ordinary bulk liquid medicines.

[0030] 6. Gentle and adaptable, with a wide audience. The formula is free of hormones, heavy metals, and irritating additives. It is gentle and suitable for oily, dry, and sensitive scalps. It can balance the scalp's oil and moisture, soothe redness and itching, and will not damage the scalp barrier with long-term use. It is suitable for both men and women and is applicable to a wide range of people. Detailed Implementation

[0031] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0032] For androgenetic alopecia, existing minoxidil solutions and topical medications suffer from drawbacks such as easy dripping, difficulty in controlling dosage, inconvenience in carrying, and limited mechanism of action due to their single-component nature. This invention uses non-woven fabric as a carrier to load a compound medicinal solution; the active components of the solution include minoxidil and finasteride. Minoxidil dilates local blood vessels and activates resting hair follicles; finasteride inhibits 5α-reductase and reduces dihydrotestosterone levels in the scalp. Together, they work synergistically to prevent hair loss and promote hair growth. This invention innovatively uses a wet wipe formulation, with each wipe individually packaged for standardized dosage, minimizing dripping and staining of clothing. The formula incorporates solubilizers, transdermal penetration enhancers, and moisturizing stabilizers to improve the solubility and transdermal absorption efficiency of the active ingredients. The product is convenient to use, suitable for various scenarios at home and on the go, and can be used for topical intervention in androgenetic alopecia and seborrheic alopecia, showing promising industrialization prospects.

[0033] Example 1 A type of anti-hair loss and hair growth wipe containing minoxidil and finasteride, the compound medicinal liquid is composed of the following by weight percentage: The composition consists of minoxidil 1.0%, finasteride 0.01%, propylene glycol 15%, azone 1.0%, glycerol 5%, phenoxyethanol 0.1%, and the remainder is purified water.

[0034] Preparation method: S1. Preheat the purified water to 35°C and set aside. S2. Under sterile and light-protected conditions, add propylene glycol and glycerin to purified water and stir at 300 rpm for 5 minutes until dissolved; add minoxidil and finasteride and stir for 15 minutes until completely clear; add azone and phenoxyethanol and stir for 3 minutes to mix well and let stand to defoam. S3. Made of 60g / ㎡ pure cotton spunlace nonwoven fabric, impregnated under negative pressure, with drug loading controlled at 2.0g / tablet; S4. Individually sealed packaging, stored at room temperature away from light, to obtain the finished product.

[0035] Example 2 A type of anti-hair loss and hair growth wipe containing minoxidil and finasteride, the compound medicinal liquid is composed of the following by weight percentage: The formula consists of: minoxidil 3.0%, finasteride 0.25%, propylene glycol + 1,3-butanediol co-solvent 25%, azone + menthol penetration enhancer 2.0%, sodium hyaluronate + panthenol moisturizing stabilizer 10%, phenoxyethanol and ethylhexylglycerin (mass ratio 3:1) preservative 0.3%, and the remainder is purified water.

[0036] Preparation method: S1. Preheat the purified water to 40℃ and set aside; S2. Under sterile and light-protected conditions, stir at a constant speed of 400 rpm, add the solubilizer and moisturizing stabilizer in sequence, and stir for 8 minutes; add the dual active ingredients and stir for 18 minutes until completely dissolved and without precipitation; add the penetrant and preservative, stir for 4 minutes to mix well, and let stand to defoam. S3. 70g / ㎡ pure cotton non-woven fabric is selected, and it is impregnated at a constant temperature of 28℃ under negative pressure. The drug loading is 2.5g / tablet, which ensures uniform adsorption on both sides. S4. Individually sealed and packaged in a sterile environment to obtain the best finished wet wipes.

[0037] Example 3 A type of anti-hair loss and hair growth wipe containing minoxidil and finasteride, the compound medicinal liquid is composed of the following by weight percentage: The composition consists of: minoxidil 5.0%, finasteride 0.8%, anhydrous ethanol + propylene glycol cosolvent 35%, polyethylene glycol 3.0%, sodium hyaluronate 15%, ethylhexylglycerin 0.5%, and the remainder is purified water.

[0038] Preparation method: S1. Preheat purified water to 45℃ and set aside; S2. Under sterile, light-protected conditions and with stirring at 500 rpm, dissolve the cosolvent, moisturizing stabilizer, active ingredient, penetrant, and preservative in sequence, stir for 20 minutes, and let stand to defoam. S3, impregnated with 80g / ㎡ pure cotton non-woven fabric, drug loading 3.0g / tablet; S4. Seal and package to obtain the finished product.

[0039] Comparative Example 1 Commonly available 5% minoxidil tincture.

[0040] Comparative Example 2 A commercially available 0.2% finasteride topical solution.

[0041] Effect test 120 subjects aged 20-45 years with androgenetic alopecia were randomly divided into 4 groups of 30 each. Each group used the product from Example 2, Comparative Example 1, Comparative Example 2, and a blank control, respectively. The products were used twice daily, morning and evening, for 90 days. The test results are as follows: 1. User experience: The wipes of this invention are ready to use immediately, without dripping or staining clothes. 96% of the subjects reported that the ease of use is far superior to traditional tinctures and solutions; 80% of the traditional liquid medicine group had problems with uneven application and staining of clothes.

[0042] 2. Scalp adaptability: The incidence of scalp redness and itching in the group of this invention was less than 3%, and it was mild and non-irritating; the incidence of irritation in the ordinary high-concentration tincture group was 15%.

[0043] 3. Anti-hair loss effect: After 90 days, the average daily hair loss in the invention group decreased by 72%, in comparative example 1 by 45%, in comparative example 2 by 50%, and the blank group showed no significant improvement.

[0044] 4. Hair growth effect: 87% of the subjects in the invention group showed new fine and soft hair growth, and the activity of hair follicles was significantly improved; the proportion of new hair growth in the single-component group was only about 50%.

[0045] 5. Efficacy stability: After 24 months of storage at room temperature, the active ingredient retention rate of this invention is over 95%; the loss rate of active ingredients in traditional bulk liquid medicine exceeds 20%.

[0046] Comparative Example 3 The only difference from Example 2 is that the amount of anhydrous ethanol + propylene glycol cosolvent is 10%.

[0047] Comparative Example 4 The only difference from Example 2 is that the total amount of transdermal penetration enhancer azone and menthol was adjusted to 4.0%, while the other components were the same as in Example 2.

[0048] Comparative Example 5 The only difference from Example 2 is that finasteride is removed and purified water is used to make up the difference, while the other components are the same as in Example 2.

[0049] Comparative Example 6 The only difference from Example 2 is that the total amount of compound preservative added is 0.3%, the mass ratio of phenoxyethanol to ethylhexylglycerin is 1:1, and the other components are the same as in Example 2.

[0050] Comparative Example 7 The only difference from Example 2 is that the finasteride content is adjusted by 1.2%, while the other components are the same as in Example 2.

[0051] Comparative Example 8 The only difference from Example 2 is that the transdermal penetration enhancer component is removed, while the remaining components are the same as in Example 2.

[0052] In vitro transdermal experiments were conducted using isolated pig skin; stability was tested using accelerated testing: the solution was refrigerated at -5℃ for 48 hours and then kept at 45℃ for 48 hours, with five cycles to observe whether the solution became cloudy or crystals precipitated; skin irritation was tested using acute skin irritation tests on rabbit ears; and the preservative challenge was tested according to the cosmetic preservative challenge test standards.

[0053] Test samples: Example 2 (the best example) of the present invention, and comparative examples 3-8. The results are shown in Table 1.

[0054] Table 1

[0055] As shown in Table 1, in Comparative Example 3, the amount of cosolvent was reduced to 10%, which is lower than the 15%-35% range of this invention. After the accelerated stability test by thermal cycling, active ingredients crystallized out of the drug solution. This indicates that the cosolvent dosage range specified in this invention can synergistically improve the solubility stability of two poorly soluble drugs, minoxidil and finasteride. When the cosolvent is insufficient, fluctuations in the storage environment temperature can easily cause the active ingredients to precipitate out, and the distribution of the carrier drug after soaking in a wet wipe will be uneven, resulting in a decrease in actual efficacy.

[0056] As shown in Table 1, Comparative Example 8, without any transdermal penetration enhancer, achieved a transdermal penetration rate of only 9.6% after 24 hours. A large amount of drug remained on the scalp surface, resulting in insufficient drug concentration in the hair follicles and poor therapeutic effect. Comparative Example 4 increased the transdermal penetration enhancer to 4.0%, which improved the penetration rate but significantly increased the skin irritation score, causing redness and stinging, making it unsuitable for long-term topical use on the scalp. This invention, using a transdermal penetration enhancer range of 1.0%-3.0%, in conjunction with solubilizers and moisturizing stabilizers, achieves high transdermal absorption while maintaining low irritation; this demonstrates that this range is not a conventional choice but rather represents an optimal window.

[0057] Comparative Example 5 contained only minoxidil, without topical finasteride; under the same conditions, transdermal penetration decreased. Minoxidil focuses on dilating blood vessels and revitalizing hair follicles; finasteride inhibits 5α-reductase and lowers dihydrotestosterone. The combination of the two is not a simple additive; the dual-active component combination system achieves synergistic effects on different targets, and compared to the single minoxidil system, it can simultaneously inhibit the root cause of hair loss and stimulate hair follicle regeneration.

[0058] Comparative Example 6, with a phenoxyethanol to ethylhexylglycerin mass ratio of 1:1, deviated from the 2:1-4:1 protection range. While the total preservative content remained unchanged, the preservative performance failed to meet mold control standards. The excessively high proportion of ethylhexylglycerin increased the system's stickiness and skin irritation. This demonstrates that only a mass ratio of 2:1-4:1 can achieve synergistic preservative effects, reducing the amount of any single component while balancing preservative efficacy and low irritation. The desired effect cannot be achieved with any arbitrary ratio.

[0059] In Comparative Example 7, the finasteride concentration was increased to 1.2%, exceeding the upper limit of 0.01-0.8%. This resulted in slight precipitation in the system and a significant increase in skin irritation. Excessive finasteride concentration failed to further enhance efficacy and instead led to dissolution difficulties and irritation risks. This demonstrates that 0.01%-0.8% represents the safe and effective range for topical finasteride in this invention.

[0060] In summary, the components of this invention are not simply physical mixtures. The solubilizer simultaneously solubilizes and stabilizes minoxidil and finasteride; the transdermal absorption enhancer and moisturizing stabilizer work synergistically to improve transdermal absorption while buffering drug irritation; the specific mass ratio of phenoxyethanol and ethylhexylglycerin achieves synergistic preservative effects; and the two active ingredients have complementary target sites. The dosage of each component must fall within the limits defined in this invention to simultaneously achieve solubility stability, high transdermal penetration, low skin irritation, and satisfactory preservative effect. Any component deviating from the parameter range of this invention will result in problems such as precipitation, increased irritation, preservative failure, and low transdermal efficiency.

[0061] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A type of anti-hair loss and hair growth wipe, characterized in that, It includes a non-woven fabric carrier and a compound drug solution impregnated on the carrier; the compound drug solution is composed of the following components by mass percentage: Minoxidil 1.0%–5.0% Finasteride 0.01%–0.8% Cosolvent 15%–35% Transdermal penetration enhancer 1.0%–3.0% Moisturizing stabilizer 5.0%–15.0% Antibacterial and preservative agent: 0.1%–0.5% Add purified water to bring the volume to 100%.

2. The anti-hair loss and hair growth wipes according to claim 1, characterized in that, The compound drug solution is composed of the following components by mass percentage: minoxidil 3.0%, finasteride 0.25%, solubilizer 25%, transdermal penetration enhancer 2.0%, moisturizing stabilizer 10%, antibacterial preservative 0.3%, and the balance being purified water.

3. The anti-hair loss and hair growth wipes according to claim 1, characterized in that, The co-solvent is selected from one or more of propylene glycol, 1,3-butanediol, and anhydrous ethanol.

4. The anti-hair loss and hair growth wipes according to claim 1, characterized in that, The transdermal penetration enhancer is selected from one or more of azone, menthol, and polyethylene glycol 400.

5. The anti-hair loss and hair growth wipes according to claim 1, characterized in that, The moisturizing stabilizer is selected from one or more of glycerin, panthenol, and sodium hyaluronate.

6. The anti-hair loss and hair growth wipes according to claim 1, characterized in that, The antibacterial and preservative agent is phenoxyethanol, ethylhexylglycerin, or a mixture of phenoxyethanol and ethylhexylglycerin.

7. The anti-hair loss and hair growth wipes according to claim 6, characterized in that, The mass ratio of phenoxyethanol to ethylhexylglycerin in the compound system is 2:1 to 4:

1.

8. The anti-hair loss and hair growth wipes according to claim 1, characterized in that, The nonwoven fabric is a spunlace nonwoven fabric with a basis weight of 50-80 g / m². 2 The material is pure cotton or viscose fiber, and the amount of medicine soaked in a single non-woven fabric is controlled to be 2.0-3.0g.

9. The method for preparing the anti-hair loss and hair growth wipes according to any one of claims 1 to 8, characterized in that, It includes the following steps: S1. Raw material pretreatment; S2. Preparation of compound drug solution: Under a light-protected and sterile environment, add solubilizer and moisturizing stabilizer to preheated purified water and stir to dissolve; then add minoxidil and finasteride and stir thoroughly until completely dissolved; add transdermal penetration enhancer and antibacterial preservative in sequence, mix evenly and let stand to defoam; S3. Non-woven fabric impregnation: Non-woven fabric is impregnated with negative pressure to absorb the drug solution; S4. Individually sealed and light-proof packaging yields the finished anti-hair loss and hair growth wipes.

10. The preparation method according to claim 9, characterized in that, The temperature of the preheated purified water is 35-45℃, the stirring speed is 300-500 r / min, and the ambient temperature for impregnating the nonwoven fabric is 25-30℃.

Images